Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites

HIV Clinical Trials

Volumn 8, Issue 6, 2007, Pages 391-399

  Hall, David B ^a   MacGregor, Thomas R ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Liver; Nevirapine; Nevirapine oxidative metabolites; Rash

Indexed keywords

12 HYDROXYNEVIRAPINE; 2 HYDROXYNEVIRAPINE; 3 HYDROXYNEVIRAPINE; 4 CARBOXYNEVIRAPINE; 8 HYDROXYNEVIRAPINE; DIDANOSINE; DRUG METABOLITE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; PREDNISONE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANALYTIC METHOD; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION; LIVER TOXICITY; LOG RANK TEST; MALE; PRIORITY JOURNAL; RACE; RASH;

CASE-CONTROL STUDIES; EXANTHEMA; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; NEVIRAPINE; PLASMA;

EID: 37349023127     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0806-391     Document Type: Article

References (16)

1. Murphy RL. Defining the toxicity profile of nevirapine and other antiretroviral drugs. J Acquire Immune Defic Syndr. 2003;34:S15-20.
2. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquire Immune Defic Syndr. 2003;34:S21-33.
3. Kappelhoff BS, van Leth F, Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antiviral Ther. 2005;10:489-498.
4. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999;27:895-901.
5. Lamson M, MacGregor T, Riska P, et al. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin Pharmacol Ther. 1999;65:137.
6. Rowland LS, MacGregor TR, Campbell SJ, Jenkins R, Pearsall AB, Morris JP. Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography - tandem mass spectrometry. J Chromatogr B. 2007; 856:252-260.
7. Popovic M, Caswell JL, Mannargundi B, Shenton JM, Uetrecht JP. Study of the sequence of events involved in nevirapine-induced skin rash in brown Norway rats. Chem Res Toxicol. 2006;19:1205-1214.
8. Shenton JM, Teranishi M, Abu-Asab MS, Yager JA, Uetrecht JP. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem Res Toxicol. 2003;16:1078-1089.
9. Shenton JM, Popovic M, Chen J, Masson MJ, Uetrecht JP. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female brown Norway rat. Chem Res Toxicol. 2005;18:1799-1813.
10. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial. JAMA. 1998;279:930-937.
11. Montainer JSG, Cahn P, Zala C, et al. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquire Immune Defic Syndr. 2003;33:41-46.
12. Pav JW, Rowland LS, Korpalski DJ. HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction. J Pharm Biomed Anal. 1999;20:91-98.
13. Grozinger KG, Byrne DP, Nummy LJ, Ridges MD. Synthesis of five nevirapine metabolites. J Heterocyclic Chem. 2000;37:229-239.
14. Kappelhoff BS, van Leth F, MacGregor TR, Lange JMA, Huitema ADR. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antiviral Ther. 2005;10:145-155.
15. Kappelhoff BS, Huitema ADR, van Leth F, Robinson PA, MacGregor TR, Lange JMA, Beijnen JH. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials. 2005;6:254-261.
16. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol. 1992;41:1047-1055.